Research Topics
Genomes and Genes | Gregory J RielySummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 13:5150-5. 2007..In these patients, we sought to assess changes in tumor metabolism and size after stopping and restarting erlotinib or gefitinib and to determine the effect of adding everolimus...
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinomaGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 14:5731-4. 2008..These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib...
Induction therapy for locally advanced thymomaGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Thorac Oncol 5:S323-6. 2010..In this review, we summarize the published experience with preoperative therapy for thymoma and discuss ongoing clinical trials exploring multimodality therapy for treatment of locally advanced thymoma...- A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutationsGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
J Thorac Oncol 6:1435-7. 2011..Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations... - Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancerGregory J Riely
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10022, USA
J Clin Oncol 27:264-70. 2009..However, preclinical data support the hypothesis that intermittent administration of erlotinib before or after chemotherapy may improve efficacy. We tested this hypothesis in patients with advanced NSCLC... - Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerGregory J Riely
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Thorac Oncol 3:S146-9. 2008..The preliminary results from phase I and phase II trials for BIBW-2992 and XL647 are discussed... - Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profilingJamie E Chaft
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
Mol Cancer Ther 11:485-91. 2012..Given the high frequency of overlapping mutations, comprehensive genotyping should be carried out on tumor specimens from patients enrolling in clinical trials of PI3K and other targeted therapies... - Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsMarissa N Balak
Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Varmus Lab, Department of Pathology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 12:6494-501. 2006..Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anatomic site and mode of binding to the kinase target... - A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionPaul K Paik
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY 10065, USA
Cancer Chemother Pharmacol 68:1331-7. 2011..We sought to determine if the incidence and severity of peripheral neuropathy could be reduced when the infusion time is lengthened to 2-h... - Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancerDaniel T Milton
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
Cancer 110:599-605. 2007..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)... - Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancerKatharine A Price
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York City, New York, USA
J Thorac Oncol 5:1623-9. 2010..This phase II trial assessed the efficacy of the combination of gefitinib and everolimus in patients with advanced NSCLC... - Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomasPaul K Paik
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 118:5840-7. 2012..In this study, the authors hypothesized that smoking-dependent differences in the distribution of driver mutations may explain differences in prognosis between these subgroups... - Insulin-like growth factor-1 receptor expression in thymic malignanciesNicolas Girard
Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
J Thorac Oncol 5:1439-46. 2010..As higher levels of IGF-1R protein expression may be associated with relative sensitivity to anti-IGF-1R antibody treatment, we investigated IGF-1R expression in thymic malignancies... - Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationGeoffrey R Oxnard
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
Clin Cancer Res 17:1616-22. 2011..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI... - Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaJames Bean
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 14:7519-25. 2008..We aimed to identify additional second-site alterations associated with acquired resistance... - EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expressionAllan R Li
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Mol Diagn 10:242-8. 2008..Thus, these results indicate that EGFR amplification, preferentially of the mutant allele, often accompanies EGFR mutation, whereas EGFR immunohistochemical staining associates with amplification but cannot predict EGFR mutation status... - Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomasSandra P D'Angelo
Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
J Clin Oncol 29:2066-70. 2011..EGFR mutations underlie the sensitivity of lung cancers to erlotinib and gefitinib and can occur in any patient with this illness. Here we examine the frequency of EGFR mutations in smokers and men... - Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 26:1472-8. 2008..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response... - Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibGregory J Riely
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 12:839-44. 2006..We undertook this study to explore the relationship between EGFR mutation type and clinical variables, including treatment with gefitinib and erlotinib... - Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomasDuyKhanh Pham
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 24:1700-4. 2006..Investigators have reported an association between EGFR mutations and the amount and duration of cigarette smoking, with the highest incidence of mutations seen in never smokers... - Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinibYelena Y Janjigian
Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
Clin Cancer Res 17:2521-7. 2011..To evaluate the toxicity and efficacy of cetuximab and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II clinical trial... - Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibGeoffrey R Oxnard
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
Clin Cancer Res 17:6322-8. 2011..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI... - Molecular on/off switchDaniel T Milton
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University, New York, NY, USA
J Clin Oncol 24:4940-2. 2006 - Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African AmericansJ Matthew Reinersman
Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
J Thorac Oncol 6:28-31. 2011..KRAS mutations confer resistance to EGFR-tyrosine kinase inhibitors. The prevalence of these mutations in African American patients has not been thoroughly investigated... - Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutesGeoffrey R Oxnard
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 29:3114-9. 2011..In this study, we assess the variability of lung tumor measurement using repeat CT scans performed within 15 minutes of each other and discuss the implications of this variability in a clinical context... - Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainWilliam Pao
Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
PLoS Med 2:e73. 2005..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance... - Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancerM Catherine Pietanza
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
J Thorac Oncol 7:856-65. 2012..We undertook an open-label, multi-institutional Phase II study to investigate the efficacy and safety of XL647 in treatment-naive non-small-cell lung cancer patients clinically enriched for the presence of EGFR mutations... - Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayMaria E Arcila
Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 17:1169-80. 2011..Using high sensitivity methods, the T790M is detected in up to 68% of these patients... - KRAS mutational testing in the selection of patients for EGFR-targeted therapiesJoaquin Garcia
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Semin Diagn Pathol 25:288-94. 2008.... - Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I casesAkihiko Yoshizawa
Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Mod Pathol 24:653-64. 2011..The slightly stronger association with survival for invasive size versus gross size raises the need for further studies to determine whether this adjustment in measuring tumor size could impact TNM staging for small adenocarcinomas... - Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial designJamie E Chaft
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
Clin Cancer Res 17:6298-303. 2011..To examine this observation and define the course of patients following TKI discontinuation, we systematically evaluated patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib... - Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimensCarlie S Sigel
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
J Thorac Oncol 6:1849-56. 2011..The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction... - KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibWilliam Pao
Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
PLoS Med 2:e17. 2005..Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive... - Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancerNaiyer A Rizvi
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 26:639-43. 2008..We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patients with stage IV non-small-cell lung cancer (NSCLC)... - A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapyGregory J Riely
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Lung Cancer 55:181-5. 2007..TZT-1027, a derivative of dolastatin-10, has a wide spectrum of in vitro activity against cancer cell lines. We conducted a phase 2 trial of TZT-1027 in patients with previously treated non-small cell lung cancer (NSCLC)... - A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinomaKyuichi Kadota
Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Mod Pathol 25:1117-27. 2012..005) after adjusting for clinical factors. We proposed this combined architectural/mitotic grade for lung adenocarcinoma as a practical method that can be applied in routine practice... - KRAS mutations in non-small cell lung cancerGregory J Riely
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Proc Am Thorac Soc 6:201-5. 2009..In this review, we summarize the initial discovery of RAS mutations in NSCLC, describe work exploring associations with clinical factors and outcomes, and provide an overview of current approaches to targeting KRAS mutant NSCLC... - Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancerYelena Y Janjigian
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 116:670-5. 2010.... - Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testingNatasha Rekhtman
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
J Thorac Oncol 6:451-8. 2011..The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice... - Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutationsPaul K Paik
Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
J Clin Oncol 29:2046-51. 2011..Therapies targeting BRAF mutant tumors have recently been identified. We undertook this study to determine the clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations... - Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and ErlotinibSandra P D'Angelo
Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service and Departments of Epidemiology and Biostatistics, Surgery, and Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
J Thorac Oncol 7:1815-22. 2012..The clinical significance of these mutations in patients with resected stage I-III lung cancers is unclear... - Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarkerM Catherine Pietanza
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
Clin Cancer Res 18:1138-45. 2012..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)... - Update on epidermal growth factor receptor mutations in non-small cell lung cancerGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 12:7232-41. 2006..Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions... - Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomasNicolas Girard
Human Oncology and Pathogenesis Program HOPP, Weill Medical College of Cornell University, New York, New York, USA
Clin Cancer Res 15:6790-9. 2009..However, whether the underlying biology of these tumors warrants such clustering is unclear, and the optimum treatment of either entity is unknown... - Comparison of patterns of relapse in thymic carcinoma and thymomaJames Huang
Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Thorac Cardiovasc Surg 138:26-31. 2009..We reviewed our recent experience with the surgical management of thymic tumors and compared the outcomes and patterns of relapse between patients with thymic carcinoma and those with thymoma... - Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitorsHelena A Yu
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA
J Thorac Oncol 8:346-51. 2013..Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI... - Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi
Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Proc Natl Acad Sci U S A 109:E2127-33. 2012.... - Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersSnjezana Dogan
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 18:6169-77. 2012..The molecular epidemiology of most EGFR and KRAS mutations in lung cancer remains unclear... - The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutationsGregory J Riely
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Lung Cancer 60:S19-22. 2008..Improved understanding of the association of EGFR mutations with clinical outcome may improve the ability of physicians to match treatment to mutation status for patients with NSCLC... - Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancerBinsheng Zhao
Departments of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
Radiology 252:263-72. 2009..To evaluate the variability of tumor unidimensional, bidimensional, and volumetric measurements on same-day repeat computed tomographic (CT) scans in patients with non-small cell lung cancer... - Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancersAnna M Varghese
Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Thorac Oncol 8:123-5. 2013.... - Management and outcomes of relapse after treatment for thymoma and thymic carcinomaMatthew J Bott
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Ann Thorac Surg 92:1984-91; discussion 1991-2. 2011..Although surgery is the mainstay of treatment for thymic tumors, recurrence is common despite resection. The optimal approach to the management of disease relapse after treatment for thymic tumors remains unclear... - Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?Gregory J Riely
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Biol Ther 4:1096-7. 2005 - Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysisNoriko Motoi
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Am J Surg Pathol 32:810-27. 2008..Such an approach should be considered in future studies for validation in other datasets... - Vascular endothelial growth factor trap in non small cell lung cancerGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College of Cornell University, New York, New York 10022, USA
Clin Cancer Res 13:s4623-7. 2007..Ongoing phase I trials are evaluating combinations of VEGF Trap with platinum-based doublets and single-agent docetaxel. The activity of single-agent VEGF Trap in NSCLC is being assessed in a multicenter phase II trial... - International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaWilliam D Travis
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Thorac Oncol 6:244-85. 2011.... - KRAS mutations: an old oncogene becomes a new predictive biomarkerGregory J Riely
Thoracic Oncology Service, Department of Medicine, New York, New York, USA
J Mol Diagn 10:493-5. 2008..This commentary highlights a novel assay for detection of mutations in KRAS, which have recently emerged as a useful negative predictive biomarker... - Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancersHelena A Yu
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Natl Compr Canc Netw 11:161-9. 2013.... - Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy?James Huang
Ann Thorac Surg 85:365-7. 2008 - Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
J Thorac Oncol 3:S107-12. 2008..A CME activity based on this summary is also available at www.informedicalcme.com/cme... - EGFR mutant lung adenocarcinomas in patients with germline BRCA mutationsJenifer L Marks
J Thorac Oncol 3:805. 2008 - Novel agents in the treatment of lung cancer: Fourth Cambridge ConferenceThomas J Lynch
Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
Clin Cancer Res 13:s4583-8. 2007....